BioMarin Pharmaceutical Inc (BMRN) stock
BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3091% above fair value
$57.23+0.53 (+0.93%)
Close on Nov 13, 2026Market cap $11.08BP/E 150.6Yield –
BioMarin Pharmaceutical ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
BioMarin Pharmaceutical's ebitda for the twelve months ending Jun 30, 2026 was $302.23M, down 64.8% year over year. For fiscal 2025 it was $489.04M, down 15.8% from the year before. The highest annual figure on record is $580.64M in fiscal 2024.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $489.04M | -15.8% |
| FY2024 | Dec 31, 2024 | $580.64M | +100.1% |
| FY2023 | Dec 31, 2023 | $290.16M | +10.4% |
| FY2022 | Dec 31, 2022 | $262.94M | +923.2% |
| FY2021 | Dec 31, 2021 | $25.70M | -58.4% |
| FY2020 | Dec 31, 2020 | $61.73M | +1174.7% |
| FY2019 | Dec 31, 2019 | $4.84M | – |
| FY2018 | Dec 31, 2018 | -$27.85M | -138.1% |
| FY2017 | Dec 31, 2017 | $73.16M | – |
| FY2016 | Dec 31, 2016 | -$706.52M | – |
| FY2015 | Dec 31, 2015 | -$63.52M | – |
| FY2014 | Dec 31, 2014 | -$47.02M | – |
| FY2013 | Dec 31, 2013 | -$119.99M | – |
| FY2012 | Dec 31, 2012 | -$65.88M | -5799.0% |
| FY2011 | Dec 31, 2011 | $1.16M | -95.9% |
| FY2010 | Dec 31, 2010 | $28.28M | -24.4% |
| FY2009 | Dec 31, 2009 | $37.40M | -34.8% |
| FY2008 | Dec 31, 2008 | $57.37M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $208.56M | -29.4% |
| Q1 FY2026 | Mar 31, 2026 | $146.05M | -40.6% |
| Q4 FY2025 | Dec 31, 2025 | -$24.17M | -113.1% |
| Q3 FY2025 | Sep 30, 2025 | -$28.21M | -121.2% |
| Q2 FY2025 | Jun 30, 2025 | $295.45M | +101.1% |
| Q1 FY2025 | Mar 31, 2025 | $245.96M | +112.4% |
| Q4 FY2024 | Dec 31, 2024 | $185.01M | +241.7% |
| Q3 FY2024 | Sep 30, 2024 | $132.90M | +136.4% |
| Q2 FY2024 | Jun 30, 2024 | $146.92M | +61.5% |
| Q1 FY2024 | Mar 31, 2024 | $115.81M | +30.4% |
| Q4 FY2023 | Dec 31, 2023 | $54.14M | +372.2% |
| Q3 FY2023 | Sep 30, 2023 | $56.21M | +151.1% |
| Q2 FY2023 | Jun 30, 2023 | $90.99M | +41.2% |
| Q1 FY2023 | Mar 31, 2023 | $88.83M | -46.1% |
| Q4 FY2022 | Dec 31, 2022 | $11.47M | – |
| Q3 FY2022 | Sep 30, 2022 | $22.39M | – |
| Q2 FY2022 | Jun 30, 2022 | $64.42M | +65.6% |
| Q1 FY2022 | Mar 31, 2022 | $164.67M | +210.3% |
| Q4 FY2021 | Dec 31, 2021 | -$39.89M | – |
| Q3 FY2021 | Sep 30, 2021 | -$26.38M | – |
| Q2 FY2021 | Jun 30, 2021 | $38.90M | – |
| Q1 FY2021 | Mar 31, 2021 | $53.07M | -59.5% |
| Q4 FY2020 | Dec 31, 2020 | -$24.16M | -245.3% |
| Q3 FY2020 | Sep 30, 2020 | -$29.31M | -184.3% |
| Q2 FY2020 | Jun 30, 2020 | -$15.73M | – |
| Q1 FY2020 | Mar 31, 2020 | $130.93M | – |
| Q4 FY2019 | Dec 31, 2019 | $16.63M | – |
| Q3 FY2019 | Sep 30, 2019 | $34.75M | +227.7% |
| Q2 FY2019 | Jun 30, 2019 | -$15.01M | – |
| Q1 FY2019 | Mar 31, 2019 | -$31.52M | – |
| Q4 FY2018 | Dec 31, 2018 | -$13.43M | -115.5% |
| Q3 FY2018 | Sep 30, 2018 | $10.60M | +52.1% |
| Q2 FY2018 | Jun 30, 2018 | -$4.29M | – |
| Q1 FY2018 | Mar 31, 2018 | -$20.74M | – |
| Q4 FY2017 | Dec 31, 2017 | $86.71M | – |
| Q3 FY2017 | Sep 30, 2017 | $6.97M | – |
| Q2 FY2017 | Jun 30, 2017 | -$19.73M | – |
| Q1 FY2017 | Mar 31, 2017 | -$796.00K | – |
| Q4 FY2016 | Dec 31, 2016 | -$69.51M | – |
| Q3 FY2016 | Sep 30, 2016 | -$30.66M | – |
See a number that looks wrong?